Herein, we report the oncogenic role of GREM1 in breast cancer growth and progression. Notably, GREM1 induces transcriptional activity of ERRα through EGFR activation, which in turn upregulates GREM1 expression
Breast cancer growth and progression were accelerated following stimulation of sympathetic nerves in tumors, but were reduced following stimulation of parasympathetic nerves. Tumor-specific sympathetic denervation suppressed tumor growth and downregulated the expression of immune checkpoint molecules (programed ...
We calculated age-for-grade based on whether a child was on, over, or under the expected age for a grade. Generalised estimating equations estimated the average effect of EBF on age-for-grade. Latent class growth modelling identified age-for-grade trajectories, and multinomial logistic regression...
One key characteristic of the Luminal A breast cancer subtypes is the relatively low levels of the Ki-67 protein, a prognostic and predictive indicator of tumor cell proliferation and growth [1]. Luminal A breast cancers are often slow growing and are not typically treated with chemotherapy as ...
Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138:241–56.https://doi.org/10.5858/arpa.2013-0953-SA. ...
Two separate doses of single-agent camizestrant monotherapy improved progression-free survival vs standard-of-care fulvestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.
While it is well accepted that obesity-related inflammation promotes ER activity in the breast by increasing local E2 levels, obesity may also alter the profile of stromal growth factors that can activate the ER in the absence of its cognate ligand. Fibroblast growth factors, IGF-1, and EGF,...
or no intervention in postmenopausal women with >25% breast density. No change with Lovaza™ has been found in the first 46 women in secondary endpoint blood risk biomarkers such as insulin-like growth factor I and insulin-like growth factor-binding protein 3 or the inflammatory marker high-...
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression Nat Genet, 9 (1995), pp. 444-450 View in ScopusGoogle Scholar 42. P. Freneaux, D. Stoppa-Lyonnet, E. Mouret, et al. Low expression of bcl-2 in Brca1-associated breast cancers...
Breast cancer is the most common malignant tumor among women worldwide. Although increasing evidence indicates that long noncoding RNAs (lncRNAs) play critical roles during breast tumorigenesis and progression, the involvement of most lncRNAs in breast c